These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1446 related items for PubMed ID: 22956068

  • 1. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE.
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [Abstract] [Full Text] [Related]

  • 2. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 3. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 10; 32(7):520-5. PubMed ID: 21029696
    [Abstract] [Full Text] [Related]

  • 4. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.
    Clin Oncol (R Coll Radiol); 2012 Apr 10; 24(3):183-9. PubMed ID: 21958729
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, Arnold B, Eaton A, Catalano J, McCormick B, Powell S, Ho A.
    Ann Surg Oncol; 2012 Nov 10; 19(12):3762-70. PubMed ID: 22576064
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ, Truong PT, Sadek BT, Alexander CS, Wiksyk B, Shenouda M, Raad RA, Taghian AG.
    Ann Surg Oncol; 2014 Oct 10; 21(11):3490-6. PubMed ID: 24841346
    [Abstract] [Full Text] [Related]

  • 10. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
    Wang SY, Peng DF, Cai ZG, Zhang RZ, Yao TJ, Zhang H, Yang M, Dong HM.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 10; 30(3):203-6. PubMed ID: 18756937
    [Abstract] [Full Text] [Related]

  • 11. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
    Cancer; 2006 Aug 15; 107(4):696-704. PubMed ID: 16826579
    [Abstract] [Full Text] [Related]

  • 12. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS, Morrow M, Gemignani ML.
    Ann Surg Oncol; 2010 Apr 15; 17(4):1063-8. PubMed ID: 20033325
    [Abstract] [Full Text] [Related]

  • 13. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 15; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 14. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.
    Cancer; 2004 Jun 01; 100(11):2317-27. PubMed ID: 15160334
    [Abstract] [Full Text] [Related]

  • 15. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC, Ampil F, Burton G, Li BD, Chu QD.
    Surgery; 2010 Aug 01; 148(2):386-91. PubMed ID: 20580045
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA, Genovesi D, Trignani M, DI Nicola M.
    Anticancer Res; 2014 Mar 01; 34(3):1207-12. PubMed ID: 24596361
    [Abstract] [Full Text] [Related]

  • 18. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.
    Breast Cancer Res Treat; 2010 Nov 01; 124(1):187-94. PubMed ID: 20814819
    [Abstract] [Full Text] [Related]

  • 19. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.
    Zhonghua Zhong Liu Za Zhi; 2011 May 01; 33(5):381-4. PubMed ID: 21875471
    [Abstract] [Full Text] [Related]

  • 20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 01; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.